DK3750893T3 - Dioxazolinforbindelse, fremgangsmåde til fremstilling deraf og anvendelser deraf - Google Patents

Dioxazolinforbindelse, fremgangsmåde til fremstilling deraf og anvendelser deraf Download PDF

Info

Publication number
DK3750893T3
DK3750893T3 DK19751025.8T DK19751025T DK3750893T3 DK 3750893 T3 DK3750893 T3 DK 3750893T3 DK 19751025 T DK19751025 T DK 19751025T DK 3750893 T3 DK3750893 T3 DK 3750893T3
Authority
DK
Denmark
Prior art keywords
preparation
dioxazoline compound
dioxazoline
compound
Prior art date
Application number
DK19751025.8T
Other languages
Danish (da)
English (en)
Inventor
Qiang Zhang
Shannan Yu
Zhongxiang Wang
Shouye Feng
Yueming Sun
Yansheng Liu
Hongbo Zhang
Leifu Yang
Hailong Yang
Likai Zhou
Nanqiao Zheng
Chenming Hu
Zhanqiang Xu
Original Assignee
Beijing Scitech Mq Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2018/076233 external-priority patent/WO2018153293A1/zh
Application filed by Beijing Scitech Mq Pharmaceuticals Ltd filed Critical Beijing Scitech Mq Pharmaceuticals Ltd
Priority claimed from PCT/CN2019/073260 external-priority patent/WO2019154133A1/zh
Application granted granted Critical
Publication of DK3750893T3 publication Critical patent/DK3750893T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK19751025.8T 2017-02-27 2019-01-25 Dioxazolinforbindelse, fremgangsmåde til fremstilling deraf og anvendelser deraf DK3750893T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201710107756 2017-02-27
PCT/CN2018/076233 WO2018153293A1 (zh) 2017-02-27 2018-02-11 二噁烷并喹唑啉与二噁烷并喹啉类化合物及其制备方法与应用
CN201810983341.3A CN110156803A (zh) 2017-02-27 2018-08-27 二噁烷并喹啉类化合物及其制备方法与应用
PCT/CN2019/073260 WO2019154133A1 (zh) 2018-02-11 2019-01-25 二噁烷并喹啉类化合物及其制备方法与应用

Publications (1)

Publication Number Publication Date
DK3750893T3 true DK3750893T3 (da) 2023-05-08

Family

ID=63374400

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19751025.8T DK3750893T3 (da) 2017-02-27 2019-01-25 Dioxazolinforbindelse, fremgangsmåde til fremstilling deraf og anvendelser deraf

Country Status (5)

Country Link
CN (3) CN108503650B (zh)
AU (1) AU2019218187B2 (zh)
DK (1) DK3750893T3 (zh)
ES (1) ES2945573T3 (zh)
SG (1) SG11202007554TA (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11731946B2 (en) 2017-10-19 2023-08-22 The General Hospital Corporation Broad spectrum antivirulence, anti-persistence compounds
CN110156804B (zh) * 2018-02-11 2021-01-12 北京赛特明强医药科技有限公司 一种二噁烷并喹啉类化合物及其制备方法
CN111196814B (zh) * 2018-11-19 2022-12-06 北京赛特明强医药科技有限公司 芳环连二噁烷并喹唑啉或喹啉类化合物、组合物及其应用
CN111004257B (zh) * 2019-12-24 2021-06-29 武汉九州钰民医药科技有限公司 制备RET抑制剂Selpercatinib的方法
CN112939995A (zh) * 2021-02-02 2021-06-11 北京工业大学 二噁烷并喹唑啉衍生物制备方法
CN114957136A (zh) * 2021-02-24 2022-08-30 南京科默生物医药有限公司 一种用作vegfr抑制剂的抗肿瘤化合物及其用途
WO2024094016A1 (zh) * 2022-11-01 2024-05-10 北京赛特明强医药科技有限公司 一种二噁烷并喹啉类化合物的盐、其晶型以及它们的制备方法及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2371383T3 (es) * 2003-09-26 2011-12-30 Exelixis, Inc. N-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]quinolin-4-il}oxi)fenil]-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida para el tratamiento del cáncer.
US8664244B2 (en) * 2010-09-12 2014-03-04 Advenchen Pharmaceuticals, LLC Compounds as c-Met kinase inhibitors
WO2012044572A1 (en) * 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration- resistant prostate cancer and osteoblastic bone metastases
CN104530063B (zh) * 2015-01-13 2017-01-18 北京赛特明强医药科技有限公司 喹唑啉并杂环类化合物及其制备方法和作为用于治疗癌症的表皮生长因子受体抑制剂的应用
CN106279147A (zh) * 2015-05-21 2017-01-04 中国科学院上海药物研究所 一种吡啶并氮杂环化合物及其制备方法和用途
CN105837586B (zh) * 2015-12-14 2018-02-13 北京赛特明强医药科技有限公司 二噁烷并喹唑啉胺类化合物及其制备方法和作为表皮生长因子受体抑制剂的应用
CN105541798B (zh) * 2016-02-03 2018-01-23 中国人民解放军第二军医大学 具有抗肿瘤活性的喹啉类多靶点激酶抑制剂及其制备方法
WO2018153293A1 (zh) * 2017-02-27 2018-08-30 北京赛特明强医药科技有限公司 二噁烷并喹唑啉与二噁烷并喹啉类化合物及其制备方法与应用

Also Published As

Publication number Publication date
CN111788207A (zh) 2020-10-16
CN111788207B (zh) 2021-03-23
CN108503650A (zh) 2018-09-07
CN108503650B (zh) 2021-02-12
CN110156803A (zh) 2019-08-23
SG11202007554TA (en) 2020-09-29
ES2945573T3 (es) 2023-07-04
AU2019218187B2 (en) 2021-10-14
AU2019218187A1 (en) 2020-09-10

Similar Documents

Publication Publication Date Title
DK3676297T3 (da) Forbindelser, sammensætninger og fremgangsmåder
DK3312177T3 (da) Tricyklisk derivatforbindelse, fremgangsmåde til at fremstille samme og farmaceutisk sammensætning omfattende samme
DK3356390T3 (da) Fremgangsmåder og sammensætninger til virusvektorer, der undgår antistoffer
DK3407888T3 (da) Pyridopyrroloquinoxalinforbindelser, deres sammensætninger og anvendelser
DK3292150T3 (da) Aktiverbare anti-cd166-antistoffer og fremgangsmåder til anvendelse deraf
DK3659590T3 (da) Sammensætning, partikelformede materialer og fremgangsmåder til fremstilling af partikelformede materialer
DK3621229T3 (da) Fremgangsmåde til delvis retransmission
DK3360878T3 (da) Azetidinderivat, fremstillingsfremgangsmåde derfor og anvendelse deraf
DK3161124T3 (da) Endofytter, associerede sammensætninger og fremgangsmåder til anvendelse deraf
DK3750893T3 (da) Dioxazolinforbindelse, fremgangsmåde til fremstilling deraf og anvendelser deraf
DK3580561T3 (da) Hla-baserede metoder, sammensætninger og anvendelse heraf
DK3204386T3 (da) Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed
DK3168283T3 (da) Hydrokrakning-katalysator, fremstillingsfremgangsmåde og anvendelse deraf
DK3072835T3 (da) Fremgangsmåde til fremføring
DK3408326T3 (da) Elastomerartikler, sammensætninger og fremgangsmåder til fremstilling deraf
DK3113797T3 (da) Antistoffer, anvendelser og fremgangsmåder
DK3330258T3 (da) 1, 3, 5-triazinderivat og fremgangsmåde til anvendelse af samme
DK3424924T3 (da) Ureaforbindelse, fremgangsmåde til fremstilling deraf og medicinsk anvendelse deraf
DK3265123T3 (da) Antistoffer, anvendelser og fremgangsmåder
DK3223796T3 (da) Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
DK3265443T3 (da) Pyrrolidincarboxamidderivater og fremgangsmåde til fremstilling og anvendelse af samme
DK3606936T3 (da) Fremgangsmåde til indvinding
DK3142386T3 (da) Tætningsørestykke
DK3662925T3 (da) Sammensætning, der omfatter fsh, til behandling af infertilitet
DK3383397T3 (da) Farmaceutiske sammensætninger indeholdende doravirin, tenofovirdisoproxilfumarat og lamivudin